FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285390300> ?p ?o ?g. }

• W4285390300 endingPage "1340" @default.
• W4285390300 startingPage "1340" @default.
• W4285390300 abstract "With the advent of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs), Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now a relatively favorable-risk acute leukemia. In this review, we discuss the current evidence for frontline therapies of Ph-positive ALL, the major principles that guide therapy, and the progress with chemotherapy-free regimens.Incorporating TKIs into the chemotherapy regimens of patients with newly diagnosed Ph-positive ALL has led to improved remission rates, higher probability of reaching allogeneic stem cell transplantation (SCT), and longer survival compared with chemotherapy alone. Early achievement of a complete molecular remission (CMR) is an important end point in Ph-positive ALL and identifies patients who have excellent long-term survival and may not need allogeneic SCT. Second-generation TKIs combined with intensive or low-intensity chemotherapy resulted in higher CMR rates compared with imatinib-based regimens. This translated into better outcomes, with less reliance on allogeneic SCT. To further improve the outcomes, the potent third-generation TKI ponatinib was added to chemotherapy. The combination of hyper-CVAD and ponatinib resulted in an overall CMR rate of 84% and a 5-year survival rate of 73% and 86% among patients who did and did not undergo allogeneic SCT, respectively, suggesting that allogeneic SCT may not be needed with this regimen. The recent chemotherapy-free combination of dasatinib and blinatumomab was safe and effective in patients with newly diagnosed Ph-positive ALL and resulted in an estimated 3-year OS rate of 80%; 50% of patients underwent allogeneic SCT. The chemotherapy-free regimen of ponatinib and blinatumomab resulted in a CMR rate of 86% and a 2-year survival rate of 93%, with no relapses or leukemia-related deaths, and with only 1 patient proceeding to allogeneic SCT.The promising results obtained with the chemotherapy-free regimens of blinatumomab plus TKIs question the role of allogeneic SCT in first remission. Patients with Ph-positive ALL who achieve early and deep molecular responses have excellent long-term outcomes and may not benefit from allogeneic SCT." @default.
• W4285390300 created "2022-07-14" @default.
• W4285390300 creator A5049385583 @default.
• W4285390300 creator A5050914134 @default.
• W4285390300 creator A5090435894 @default.
• W4285390300 date "2022-09-01" @default.
• W4285390300 modified "2023-10-16" @default.
• W4285390300 title "Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens" @default.
• W4285390300 cites W1506738181 @default.
• W4285390300 cites W1673031009 @default.
• W4285390300 cites W1838408716 @default.
• W4285390300 cites W1931165463 @default.
• W4285390300 cites W1971329629 @default.
• W4285390300 cites W1972060994 @default.
• W4285390300 cites W1993808217 @default.
• W4285390300 cites W2000116184 @default.
• W4285390300 cites W2030796837 @default.
• W4285390300 cites W2033862877 @default.
• W4285390300 cites W2039201527 @default.
• W4285390300 cites W2056639876 @default.
• W4285390300 cites W2058216377 @default.
• W4285390300 cites W2065851457 @default.
• W4285390300 cites W2087090648 @default.
• W4285390300 cites W2102929198 @default.
• W4285390300 cites W2105098746 @default.
• W4285390300 cites W2110648386 @default.
• W4285390300 cites W2135492799 @default.
• W4285390300 cites W2139499066 @default.
• W4285390300 cites W2148854558 @default.
• W4285390300 cites W2340233667 @default.
• W4285390300 cites W2344488712 @default.
• W4285390300 cites W2406225326 @default.
• W4285390300 cites W2419639370 @default.
• W4285390300 cites W2485785171 @default.
• W4285390300 cites W2505271009 @default.
• W4285390300 cites W2553733580 @default.
• W4285390300 cites W2566332174 @default.
• W4285390300 cites W2583392141 @default.
• W4285390300 cites W2591709377 @default.
• W4285390300 cites W2598024096 @default.
• W4285390300 cites W2624795372 @default.
• W4285390300 cites W2745344769 @default.
• W4285390300 cites W2766992351 @default.
• W4285390300 cites W2772901965 @default.
• W4285390300 cites W2788740799 @default.
• W4285390300 cites W2790692615 @default.
• W4285390300 cites W2806544610 @default.
• W4285390300 cites W2809629567 @default.
• W4285390300 cites W2902317207 @default.
• W4285390300 cites W2909905103 @default.
• W4285390300 cites W2914705356 @default.
• W4285390300 cites W2986868459 @default.
• W4285390300 cites W2988192034 @default.
• W4285390300 cites W3000081737 @default.
• W4285390300 cites W3033565404 @default.
• W4285390300 cites W3083890810 @default.
• W4285390300 cites W3093938683 @default.
• W4285390300 cites W3097687160 @default.
• W4285390300 cites W3108997239 @default.
• W4285390300 cites W3119368005 @default.
• W4285390300 cites W3128092404 @default.
• W4285390300 cites W3131174609 @default.
• W4285390300 cites W3171834035 @default.
• W4285390300 cites W3174693089 @default.
• W4285390300 cites W3184300286 @default.
• W4285390300 cites W3194203975 @default.
• W4285390300 cites W3205544897 @default.
• W4285390300 cites W3211929988 @default.
• W4285390300 cites W3215637673 @default.
• W4285390300 cites W4200515411 @default.
• W4285390300 cites W4210861756 @default.
• W4285390300 cites W4229794211 @default.
• W4285390300 cites W4234978404 @default.
• W4285390300 cites W4246130629 @default.
• W4285390300 cites W4281689171 @default.
• W4285390300 cites W4282592781 @default.
• W4285390300 doi "https://doi.org/10.1001/jamaoncol.2022.2398" @default.
• W4285390300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35834222" @default.
• W4285390300 hasPublicationYear "2022" @default.
• W4285390300 type Work @default.
• W4285390300 citedByCount "21" @default.
• W4285390300 countsByYear W42853903002022 @default.
• W4285390300 countsByYear W42853903002023 @default.
• W4285390300 crossrefType "journal-article" @default.
• W4285390300 hasAuthorship W4285390300A5049385583 @default.
• W4285390300 hasAuthorship W4285390300A5050914134 @default.
• W4285390300 hasAuthorship W4285390300A5090435894 @default.
• W4285390300 hasConcept C104317684 @default.
• W4285390300 hasConcept C126322002 @default.
• W4285390300 hasConcept C138626823 @default.
• W4285390300 hasConcept C143998085 @default.
• W4285390300 hasConcept C185592680 @default.
• W4285390300 hasConcept C2776694085 @default.
• W4285390300 hasConcept C2777408962 @default.
• W4285390300 hasConcept C2777583451 @default.
• W4285390300 hasConcept C2778020697 @default.
• W4285390300 hasConcept C2778336483 @default.
• W4285390300 hasConcept C2778461978 @default.

• next